Intensive glucose control and macrovascular outcomes in type 2 diabetes
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis Improved glucose control in type 2 diabetes is known to reduce the risk of microvascular events. There is, however, continuing uncertainty about its impact on macrovascular disease. The aim of these analyses was to generate more precise estimates of the effects of more-intensive, compared with less-intensive, glucose control on the risk of major cardiovascular events amongst patients with type 2 diabetes.Methods A prospectively planned group-level meta-analysis in which characteristics of trials to be included, outcomes of interest, analyses and subgroup definitions were all pre-specified.Results A total of 27,049 participants and 2,370 major vascular events contributed to the meta-analyses. Allocation to more-intensive, compared with less-intensive, glucose control reduced the risk of major cardiovascular events by 9% (HR 0.91, 95% CI 0.84-0.99), primarily because of a 15% reduced risk of myocardial infarction (HR 0.85, 95% CI 0.76-0.94). Mortality was not decreased, with non-significant HRs of 1.04 for all-cause mortality (95% CI 0.90-1.20) and 1.10 for cardiovascular death (95% CI 0.84-1.42). Intensively treated participants had significantly more major hypoglycaemic events (HR 2.48, 95% CI 1.91-3.21). Exploratory subgroup analyses suggested the possibility of a differential effect for major cardiovascular events in participants with and without macrovascular disease (HR 1.00, 95% CI 0.89-1.13, vs HR 0.84, 95% CI 0.74-0.94, respectively; interaction p = 0.04).Conclusions/interpretation Targeting more-intensive glucose lowering modestly reduced major macrovascular events and increased major hypoglycaemia over 4.4 years in persons with type 2 diabetes. The analyses suggest that glucose-lowering regimens should be tailored to the individual.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The risk of nonfatal myocardial infarction (MI) and the composite of cardiovascular death, nonfatal MI, and nonfatal stroke were reduced, whereas the risk of stroke on its own was not.9,21”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [21]
In the citing paper
“In the nonacute setting, meta-analyses indicate that intensive glycemic control with mainly non-GLP-1RA antihyperglycemic agents in T2DM can lower the risk of microvascular and certain macrovascular complications.21”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [21]
In the citing paper
“Meta-analyses of the UKPDS, ADVANCE, ACCORD, and VADT studies, including 27 049 participants, have demonstrated that lowering HbA1c reduces MACE, driven by a reduction in MI (HF and stroke risk were unaffected), and decreases microvascular complications (renal and retinal but not neuropathy).133,134”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [134]
In the citing paper
“However, glycemic control per se does not meaningfully reduce the risk for these events (54–56).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [55]
In the citing paper
“A more recent meta-analysis examined trials of intensive vs. conventional glycaemic control, but did not include PROactive, and again identified the UKPDS, ACCORD, ADVANCE, and VADT trials.449 Similar results were found with a significant reduction in CHD and CVD events, but no reduction in cardiovascular mortality or total mortality.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [449]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationWild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297 · cited 1×
“Diabetes is a serious chronic disease that is growing rapidly in prevalence and that now affects >10% of adults in developed countries [1, 2].”
BackgroundStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“The magnitude of these macrovascular risk reductions are consistent with the epidemiological relationship between HbA1c and cardiovascular events reported from observational studies in persons with diabetes [14–17].”
ResultTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Self-citationEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 13×
“ACCORD: history of stroke, myocardial infarction, angina with ischaemic changes, coronary artery bypass graft or revascularisation; ADVANCE: history of stroke, transient ischaemic attack, myocardial infarction, angina, coronary artery bypass graft, revascularisation or amputation; UKPDS: history of myocardial infarcti…”
BackgroundInfluentialSelf-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · cited 1×
“People with type 2 diabetes are two to four times more likely to develop a serious cardiovascular outcome compared with those without diabetes [3, 4].”
BackgroundTurner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014
Self-citationMeta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Metadata
- Authors
- Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., Neal, B. C., Ninomiya, T., Patel, A. A., Paul, S. K., Travert, F., & Woodward, M.
- Affiliations
- The University of Sydney (AU)
- United States Department of Veterans Affairs (US)
- Veterans Health Administration (US)
- Wake Forest University Health Sciences (US)
- Population Health Research Institute (CA)
- University of Oxford (GB)
- Assistance Publique – Hôpitaux de Paris (FR)
- Corresponding author
- Turnbull, F. M.
- ORCID
- Venue
- Diabetologia
- Published
- 2009-08-05
- Volume
- 52
- Issue
- 11
- Pages
- 2288-2298
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1983269691
- Cited by
- 1,189
- References
- 22
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 43 · 2023: 61 · 2022: 57 · 2021: 72 · 2020: 73 · 2019: 86 · 2018: 90 · 2017: 80 · 2016: 82 · 2015: 75 · 2014: 83 · 2013: 89 · 2012: 85
- FWCI
- 61.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- GlaxoSmithKline
- Sanofi
- Servier
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, macroangiopathy, cardiovascular events, myocardial infarction, hypoglycemia, all-cause mortality, cardiovascular mortality, glucose-lowering therapy, personalized treatment
- MeSH terms
- Blood Glucose, Blood Pressure, Cholesterol, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Fasting, Follow-Up Studies, Glycated Hemoglobin, Homeostasis, Humans, Patient Compliance, Treatment Outcome, Patient Selection, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intensive glucose control and macrovascular outcomes in type 2 diabetes. https://app.cochat.ai/papers/10.1007/s00125-009-1470-0
- The paper
- Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., Neal, B. C., Ninomiya, T., Patel, A. A., Paul, S. K., Travert, F., & Woodward, M. (2009). Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. https://doi.org/10.1007/s00125-009-1470-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.